CA2134428A1 - Peptides agonistes du recepteur neuropeptidique y-y2 - Google Patents

Peptides agonistes du recepteur neuropeptidique y-y2

Info

Publication number
CA2134428A1
CA2134428A1 CA 2134428 CA2134428A CA2134428A1 CA 2134428 A1 CA2134428 A1 CA 2134428A1 CA 2134428 CA2134428 CA 2134428 CA 2134428 A CA2134428 A CA 2134428A CA 2134428 A1 CA2134428 A1 CA 2134428A1
Authority
CA
Canada
Prior art keywords
leu
arg
tyr
ide
neuropeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2134428
Other languages
English (en)
Inventor
Albert Tseng
Lisa Selbie
Erica Potter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CRC for Biopharmaceutical Research Pty Ltd
Original Assignee
CRC for Biopharmaceutical Research Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CRC for Biopharmaceutical Research Pty Ltd filed Critical CRC for Biopharmaceutical Research Pty Ltd
Priority to CA 2134428 priority Critical patent/CA2134428A1/fr
Publication of CA2134428A1 publication Critical patent/CA2134428A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2134428 1994-10-26 1994-10-26 Peptides agonistes du recepteur neuropeptidique y-y2 Abandoned CA2134428A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA 2134428 CA2134428A1 (fr) 1994-10-26 1994-10-26 Peptides agonistes du recepteur neuropeptidique y-y2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2134428 CA2134428A1 (fr) 1994-10-26 1994-10-26 Peptides agonistes du recepteur neuropeptidique y-y2

Publications (1)

Publication Number Publication Date
CA2134428A1 true CA2134428A1 (fr) 1996-04-27

Family

ID=4154541

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2134428 Abandoned CA2134428A1 (fr) 1994-10-26 1994-10-26 Peptides agonistes du recepteur neuropeptidique y-y2

Country Status (1)

Country Link
CA (1) CA2134428A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0907658A1 (fr) * 1996-06-05 1999-04-14 Peptech Limited Agonistes du neuropeptide y
US5958709A (en) * 1993-12-28 1999-09-28 Synaptic Pharmaceutical Corporation Processes for identifying compounds that bind to the human Y4 receptor
WO1999051626A2 (fr) * 1998-04-03 1999-10-14 B.M.R.A. Corp. B.V. Agonistes du recepteur y2 de npy associe a une matrice
US5989834A (en) * 1994-02-03 1999-11-23 Synaptic Pharmaceutical Corporation Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US6818445B2 (en) 1994-12-02 2004-11-16 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958709A (en) * 1993-12-28 1999-09-28 Synaptic Pharmaceutical Corporation Processes for identifying compounds that bind to the human Y4 receptor
US6913892B1 (en) 1993-12-28 2005-07-05 H. Lundbeck A/S Method of obtaining compositions comprising Y4 specific compounds
US5976814A (en) * 1993-12-28 1999-11-02 Synaptic Pharmaceutical Corporation DNA encoding a human neuropeptide Y/peptide YY/pancreatic polypeptide receptor (Y4) and uses thereof
US6420532B1 (en) 1994-02-03 2002-07-16 Synaptic Pharmaceutical Corporation Method of obtaining compositions comprising Y2 specific compounds
US5989834A (en) * 1994-02-03 1999-11-23 Synaptic Pharmaceutical Corporation Uses of nucleic acid encoding neuropeptide Y/peptide YY (Y2) receptors nucleic acid encoding
US6645774B1 (en) 1994-12-02 2003-11-11 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior using compounds with afinity for the human hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
US5989920A (en) * 1994-12-02 1999-11-23 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5
US6818445B2 (en) 1994-12-02 2004-11-16 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
EP0907658A4 (fr) * 1996-06-05 2001-09-05 Peptech Ltd Agonistes du neuropeptide y
EP0907658A1 (fr) * 1996-06-05 1999-04-14 Peptech Limited Agonistes du neuropeptide y
US6713265B1 (en) 1997-06-04 2004-03-30 Synaptic Pharmaceutical Corporation Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5)
WO1999051626A3 (fr) * 1998-04-03 1999-12-29 Bmra Corp Bv Agonistes du recepteur y2 de npy associe a une matrice
WO1999051626A2 (fr) * 1998-04-03 1999-10-14 B.M.R.A. Corp. B.V. Agonistes du recepteur y2 de npy associe a une matrice

Similar Documents

Publication Publication Date Title
US11666633B2 (en) Long-acting peptide analogs
Rivier et al. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat
Havrankova et al. Insulin receptors are widely distributed in the central nervous system of the rat
Veber et al. A potent cyclic hexapeptide analogue of somatostatin
US5696093A (en) Method of treating nasal congestion using neuropeptide Y Y2 agonist peptides
Woodside et al. Effects of glucagon on general protein degradation and synthesis in perfused rat liver
FRIESEN Hypocalcemic effect of pituitary polypeptides in rabbits
Solomon et al. Bioactivity of cholecystokinin analogues: CCK-8 is not more potent than CCK-33
US20020044925A1 (en) Myoblast transfer therapy for relieving pain and for treating behavioral and perceptive abnormalities
CA2833515C (fr) Inhibiteurs dimeres de haute affinite de psd-95 en tant que neuroprotecteurs efficaces contre les lesions cerebrales liees a une ischemie et pour le traitement de la douleur
Eleftheriades et al. Regulation of procollagen metabolism in the pressure-overloaded rat heart.
WO1993003749A1 (fr) Procedes et compositions pour moduler l'action des proteines g
Fujii et al. Mechanism of vasodilation induced by alpha‐human atrial natriuretic polypeptide in rabbit and guinea‐pig renal arteries.
US5217953A (en) Vasoactive intestinal peptide antagonist
GB2194438A (en) Enchancing the bioactivity of atrial peptides
CA2134428A1 (fr) Peptides agonistes du recepteur neuropeptidique y-y2
Walter et al. Inhibition by Z-Pro-D-Leu of development of tolerance to and physical dependence on morphine in mice.
Folkers et al. Synthetic thyrotropin-releasing hormone. Activity in men and women, specificity of action, inhibition by triiodothyronine, and activity orally
Han et al. Cardiac and vascular actions of sarafotoxin S6b and endothelin-1
US20140094415A1 (en) High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants against ischemic brain damage and for treatment of pain
Holmstedt et al. PHARMACOLOGICAL PROPERTIES OF ββ‐DIMETHYL‐ACRYLOYLCHOLINE AND SOME OTHER β‐SUBSTITUTED ACRYLOYLCHOLINES
Shapira et al. Integrated autonomic and behavioral responses to L/N Ca2 (+)-channel blocker omega-conotoxin in conscious rats
Koyuncuoǧlu et al. Vasopressin release by D-aspartic acid, morphine and prolyl-leucyl-glycinamide (PLG) in DI Brattleboro rats
Karp et al. Insulin secretion in children with constitutional familial short stature
LEBOVITZ et al. Relationships between the structure and biological activities of corticotropin and related peptides: Biological activities of a synthetic eicosapeptide amide

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead